NCT00116363View on ClinicalTrials.gov

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

PHASE2UnknownINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2005

Study Completion Date

December 31, 2006

Conditions
Malignant MelanomaNeoplasm Metastasis
Interventions
GENETIC

investigational drug INGN 241

Trial Locations (1)

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

lead

Introgen Therapeutics

INDUSTRY